cvkd: the income statement

MyFinsight

Cadrenal Therapeutics, Inc. (CVKD)

For the quarter ending 2025-06-30, CVKD made $67,004 in revenue. -$3,667,287 in net income. Net profit margin of -5473.24%.

Overview

Revenue
$67,004
Net Income
-$3,667,287
Net Profit Margin
-5473.24%
EPS
-$1.87
Unit: Dollar
Revenue Breakdown
Interest and dividend income

Unit: Dollar

	2025-06-30
Research and development expenses	1,077,498
General and administrative expenses	2,656,392
Depreciation expense	401
Total operating expenses	3,734,291
Loss from operations	-3,734,291
Interest and dividend income	67,004
Total other income	67,004
Net loss and comprehensive loss	-3,667,287

Net loss per common share, basic (in dollars per share)	-1.87
Net loss per common share, diluted (in dollars per share)	-1.87
Weighted average number of common shares used in computing net loss per common share, basic (in shares)	1,961,642
Weighted average number of common shares used in computing net loss per common share, diluted (in shares)	1,961,642

Unit: Dollar

Income Statement

DownloadDownload image